Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: We present a prospective observational-real life study about the use in Movement Disorders Unit´s patients, since its commercialization in Spain (June 2017).
Background: The gold standard of pharmacological treatment in Parkinson disease is LD, but the progression of disease leads to the development of motor fluctuations. Opicapone is a new COMT-inhibitor used for motor fluctuations in PD
Method: We evaluate opicapone´s effects in 60 PD patients (26 women, 34 men, mean age 71.4 years), in combinated therapy with MAOI 51.7%, dopamine agonists 78.3%, Entacapone 15%, Amantadine 15%. Basal UPDRS-III 28.56. They presented motor complications: fluctuations 91.7%, morning-akinesia 67.2%, wearing-OFF 66.1%, unpredictable-OFF 15.3% and dyskinesias 44.1%. Change was evaluated in UPDRS-III, presence/severity of fluctuations-dyskinesias through diaries, Global Clinical Scale-CGI and SNM at 6 months.
Results: 48 patients completed the study (3 dropped out due to inefficiency and 9 due to adverse effects), observing a statistically significant decrease in fluctuations to 83%, morning akinesia 36.2%, wearing-OFF 31.9% and unpredictable-OFF 6.4%. UPDRS-III (mean 27.56) doesn´t vary significantly. Dyskinesias improve in 8 patients, appear in 3 and not vary in 11. The 8 patients who switch LD+Entacapone to LD+opicapone: 4 have dyskinesias, 3 improve and in 1 disappeared. There are no changes in Non-Motor-Symptoms (apathy, cognitive deterioration, alucinations, TCI, depression). About 60% of patients report finding themselves better, 22.2% similar and 17.8% worse with the adition of opicapone.
Conclusion: Opicapone is safe in terms of adverse effects, especially improving motor fluctuations and subjective perception of PD severity, despite we didn´t find a statistically significant improvement in UPDRS-III. The dyskinesias seem to improve/not to get worse in 93.8% of the patients with LD/CD and in 87.5% who were first treated with LD/Entacapone.
To cite this abstract in AMA style:JC. Segundo-Rodríguez, N. López-Ariztegui, MI. Morales-Casado, N. García-Alvarado, A. Avila-Fernández, J. Pérez-Matos. OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/opicapone-real-world-evidence-in-toledos-movement-disorders-unit/. Accessed November 29, 2023.
« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/opicapone-real-world-evidence-in-toledos-movement-disorders-unit/